Home Tags Mirvetuximab soravtansine

Tag: Mirvetuximab soravtansine

Paving the Way: Mirvetuximab Soravtansine + Pembrolizumab in Endometrial Cancer

At the recently held annual meeting of the American Association for Cancer Research (AACR), positive Phase 2 trial (NCT03835819) results of the combination of mirvetuximab soravtansine and the immune checkpoint inhibitor (ICI) Pembrolizumab (Keytruda®; Merck & Co) in the treatment of folate receptor-alpha (FR-α) positive recurrent microsatellite stable / mismatch repair proficient serous endometrial cancer were presented.

Mirvetuximab soravtansine Receives full FDA approval for use in treatment of...

Mirvetuximab soravtansine Receives full FDA approval for use in treatment of Certain Ovarian Cancer Patients

Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for...

Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for $10.1 Billion

Mirvetuximab Soravtansine Improves Survival in Women With Recurrent Ovarian Cancer

The MIRASOL study (ClinicalTrials.gov identifier: NCT04209855), an international phase 3 randomized clinical trial, found that mirvetuximab soravtansine (Elahere™, ImmunoGen), an antibody-drug conjugate (ADC) and microtubule inhibitor, significantly improved progression-free and overall survival for women with platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha (FRɑ) expression.
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

ASCO 2022: SORAYA Study Shows Consistent Safety Profile for Mirvetuximab Soravtansine...

Mirvetuximab soravtansine, previously know as IMGN853, shows a tumor reduction in 71.4% of patients and preliminary median overall survival of 13.8 months in high folate receptor...

ImmunoGen Submits Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer

Immunogen has submitted a Biologics License Application (BLA) under the accelerated approval pathway to the US Food and Drug Administration (FDA) for mirvetuximab soravtansine...

Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer

The Phase 3 SOROYA trial demonstrated  promising response rates with mirvetuximab soravtansine, previously known as  IMGN853, in patients with platinum-resistant ovarian cancer and high folate receptor–alpha...

Huadong Medicine and ImmunoGen Sign Strategic Agreement to Develop and Commercialize...

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly-owned subsidiary of Huadong Medicine Co., Chinese pharmaceutical company founded in 1993, have entered into an...

AACR 2020: A Next Generation of FRα-Targeting ADC Engineered to Maximize...

Preclinical data for ImmunoGen's next-generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a broad range of FRα expression...

ASCO 2020: Mirvetuximab Soravtansine + Bevacizumab Shows Encouraging Results in Recurrent...

Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853), in combination with bevacizumab (Avastin®;...

X